Provided By GlobeNewswire
Last update: Aug 27, 2025
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI).
Read more at globenewswire.comNYSE:RMD (9/8/2025, 12:21:00 PM)
278.595
+1.55 (+0.56%)
Find more stocks in the Stock Screener